Hyperprogressive Disease Caused by PD-1 Inhibitors for the Treatment of Pan-Cancer.

ABSTRACT:

Background

Nowadays, PD-1/PD-L1 inhibitors are widely used to treat various malignant tumors. However, during the immunotherapy in a few patients, a flare-up of tumor growth occurred. This new pattern of progression is called hyperprogressive disease (HPD). Patients and Methods. The retrospective study included 377 patients with various malignant tumors treated with PD-1 inhibitors (nivolumab or pembrolizumab) in the Chinese PLA General Hospital from January 2015 to January 2019. Clinicopathologic variables, tumor growth rate (TGR), and treatment outcomes were analyzed in patients with pan-cancer treated with PD-1 inhibitors. HPD was defined as the difference of TGR before and during immunotherapy exceeding 50%.

Results

In 38 of 377 patients (10.08%), HPD occurred aft

SUBMITTER: Chen S 

PROVIDER: S-EPMC8241516 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature